Aclaris Therapeutics (ACRS) vs Aquestive Therapeutics (AQST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 96.4% versus a loss of 28.6%. Over five years, AQST leads with a +23.5% price change compared with -77.2% for ACRS. Aquestive Therapeutics is the larger company by market cap ($599.9 million vs $563.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | AQST |
|---|---|---|
| Share price | $3.83 | $4.78 |
| Market cap | $563.77M | $599.95M |
| 1-day change | +1.06% | +0.42% |
| YTD return | +27.24% | -26.01% |
| 1-year return | +96.41% | -28.55% |
| 5-year return | -77.22% | +23.51% |
| EPS (TTM) | $-0.58 | $-0.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $7.55 |
| 52-week low | $1.74 | $2.93 |
| Distance from 52-week high | -41.97% | -36.69% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +165.80% | +95.19% |
| Average volume | 2.61M | 2.67M |
| Shares outstanding | 147.20M | 125.51M |
| Employees | 69 | 147 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed AQST by 125.0 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
ACRS vs AQST FAQ
Which is bigger, Aclaris Therapeutics or Aquestive Therapeutics?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $599.95M compared with $563.77M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or AQST?
ACRS returned +96.41% over the past 12 months, compared with -28.55% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Aquestive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.